Popular terms

Codon topics
Hydrocodone
Nucleic Acid
Acetaminophen
Carboxylic Acid
Benzoic Acid
Genetically
Recombinant
Amino Acid
Nucleotide
Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitor
Reverse Transcriptase
Antibodies
Base Sequence
Replication

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Codon patents



      

This page is updated frequently with new Codon-related patent applications.




Date/App# patent app List of recent Codon-related patents
07/21/16
20160205886 
Plants with an intense fruit phenotype
The present invention relates to plants comprising a modified amount, activity or function of agl11-like protein, wherein the plant is a member of plant family cucurbitaceae or of species solanum lycopersicum; characterized in that the plant is not a solanum lycopersicum plant having a deletion from nucleotide 1042 to nucleotide 637 upstream of the atg start codon of seq id no: 1.. .
Nunhems B.v.


07/14/16
20160200731 
Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
Kempharm, Inc.


07/14/16
20160199412 
Modified hepatitis post-transcriptional regulatory elements
Provided are polynucleotides containing a modified pre having a variant x gene that includes one or more stop codons not present in an unmodified, such as wild-type, hepatitis x gene. Also provided are polynucleotides containing a modified pre having a variant x gene that includes one or more degradation sequences not present in an unmodified, such as wild-type, hepatitis x gene.
Juno Therapeutics, Inc.


07/07/16
20160193204 
Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
Kempharm, Inc.


06/30/16
20160186234 
Codon-optimized gene for mutated shrimp luciferase and use thereof
There has been a demand for a codon-optimized gene for the mutated catalytic domain of oplophorus luciferase, which is capable of efficiently expressing a protein both in a cultured animal cell and escherichia coli. There has also been a demand for a substrate coelenterazine analogue showing a higher activity than that of native 19 kda protein.

06/30/16
20160186189 
Site-specific incorporation of phosphoserine into proteins in escherichia coli
Nucleic acids encoding mutant elongation factor proteins (ef-sep), phosphoseryl-trna synthetase (seprs), and phosphoseryl-trna (trnasep) and methods of use in site specific incorporation of phosphoserine into a protein or polypeptide are described. Typically, seprs preferentially aminoacylates trnasep with o-phosphoserine and the trnasep recognizes at least one codon such as a stop codon.

06/30/16
20160186188 
Methods for altering polypeptide expression and solubility
The invention is directed to methods and metric suitable for use in determining the solubility, expression and usability of a polypeptide encoded by a nucleic acid sequence. In certain aspects, the invention also relates to methods for introducing modifications in a polypeptide, for example through substitution of one or more codons in the nucleic acid sequence encoding the polypeptide, to increase or decrease the solubility, expression or usability of the polypeptide..

06/30/16
20160185790 
Process for preparing oxycodone compositions
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/30/16
20160185789 
Process for preparing oxycodone compositions
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/30/16
20160185788 
Process for preparing oxycodone compositions
In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/30/16
20160184299 

Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia


The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof..

06/30/16
20160184293 

A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation


The present invention is concerned with an oral pharmaceutical dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain in patients suffering from i) pain and at least one further disease ii), wherein said at least one further disease ii) results in intestinal dysbiosis, or for use in the treatment of pain in patients suffering from i) pain and at least one further disease iii), wherein said at least one further disease iii) increases the risk for intestinal bacterial translocation and thus for peritonitis, sirs and/or sepsis.. .

06/23/16
20160177283 

Heterologous expression of termite cellulases in yeast


The present invention provides for heterologous expression of termite and termite-associated symbiont cellulases. The cellulases can, for example, be codon-optimized and expressed in yeast host cells, such as the yeast saccharomyces cerevisiae.

06/23/16
20160176889 

Process for preparing oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/23/16
20160176888 

Process for preparing oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/23/16
20160175300 

Process for preparing oxycodone docage form


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/23/16
20160175299 

Methods of treating pain


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/23/16
20160175298 

Oxycodone dosage forms


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .

06/16/16
20160168579 

Encoding text into nucleic acid


Methods and apparatus are disclosed herein for encoding human readable text conveying a non-genetic message into nucleic acid sequences with a substantially reduced probability of biological impact and decoding such text from nucleic acid sequences. In one embodiment, each symbol of a symbol set of human readable symbols uniquely maps to a respective codon identifier.
Synthetic Genomics, Inc.


06/16/16
20160168263 

Certain improved human bispecific egfrviii antibody engaging molecules


We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human egfrviii mutant protein on its surface, and a second arm that specifically engages t cell activation ligand cd3. The polynucleotide is codon optimized for expression in cho cells.
The Government Of The U.s. As Represented By The Secretary Of Health


06/16/16
20160168160 

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone, prodrugs, methods of making and use thereof


The presently described technology provides compositions comprising aryl carboxylic acids and, for example nsaids, chemically conjugated to oxycodone (4,5-α-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxycodone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxycodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology..
Kempharm, Inc.


06/16/16
20160166677 

Computationally optimized broadly reactive antigens for h1n1 influenza


Described herein is the generation of optimized h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h1n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on selected h1n1 viruses isolated from 1918-2012.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


06/09/16
20160158224 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


06/09/16
20160158223 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


06/02/16
20160151361 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


06/02/16
20160151292 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


06/02/16
20160151288 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


05/26/16
20160145603 

Compositions for making random codon-mutant libraries and uses thereof


The present disclosure relates to compositions and methods for randomly introducing codon-mutations in a target nucleic acid molecule and, more particularly, using wild-type and triplet-randomized oligonucleotides to introduce mutations uniformly across a target nucleotide of interest in a controlled fashion and with a low rate of insertions or deletions.. .
Fred Hutchinson Cancer Research Center


05/26/16
20160143323 

Feed additive for swine and feed composition containing the same


A feed additive for swine consists of following ingredients measured by weight: 20-50 sour jujubes, 10-18 radix bupleuri, 6-20 codonopsis pilosula, 10-20 honeysuckles, 10-20 isatis roots, 4-8 anemarrhena asphodeloides, 3-6 liquorice, 10-20 myrica rubra and 30-60 cactuses. The disclosure further provides a feed composition for swine with the above feed additive.

05/26/16
20160143322 

Feed additive for swine and feed composition containing the same


A feed additive for swine consists of following ingredients measured by weight: 20-50 sour jujubes, 10-18 radix bupleuri, 6-20 codonopsis pilosula, 10-20 honeysuckles, 10-20 isatis roots, 3-6 astragalus propinquus, 10-20 myrica rubra and 30-60 cactuses. The disclosure further provides a feed composition for swine with the above feed additive.

05/26/16
20160143321 

Feed additive for swine and feed composition containing the same


A feed additive for swine consists of following ingredients measured by weight: 20-50 sour jujubes, 10-18 radix bupleuri, 6-20 codonopsis pilosula, 10-20 honeysuckles, 10-20 isatis roots, 10-18 chrysanthemums, 6-9 red jujubes, 10-20 myrica rubra and 30-60 cactuses. The disclosure further provides a feed composition for swine with the above feed additive.

05/19/16
20160137699 

Recombinant fusion antigen gene, recombinant fusion antigen protein and subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus


The present invention is directed to a recombinant fusion antigen gene, a recombinant fusion antigen protein and a subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus (prrsv). A recombinant fusion antigen gene, which encodes glycoprotein gp5 with truncated n′-terminal decoy epitope, a linker sequence and membrane protein m, followed by codon optimization, is expressed by a baculovirus expression system in vitro, thereby enhancing a yield of the recombinant fusion antigen protein.
National Pingtung University Of Science And Technology


05/19/16
20160137656 

Processes for making hydrocodone, hydromorphone and their derivatives


Improved processes for making hydrocodone and hydromorphone as well as their 8,14-dihydrothebaine and 8,14-dihydrooripavine derivatives and salts are disclosed.. .
Johnson Matthey Public Limited Company


05/19/16
20160137655 

Processes for making hydrocodone, hydromorphone and their derivatives


Improved processes for making hydrocodone and hydromorphone as well as their 8,14-dihydrothebaine and 8,14-dihydrooripavine derivatives and salts are disclosed.. .
Johnson Matthey Public Limited Company


05/19/16
20160136156 

Immediate release pharmaceutical compositions comprising oxycodone and naloxone


The present invention pertains to oral immediate release pharmaceutical compositions suitable for treating patients suffering from pain comprising oxycodone and naloxone or their pharmaceutically acceptable salts.. .
Purdue Pharma L.p.


05/19/16
20160136154 

Extended release hydrocodone acetaminophen and related methods and uses thereof


The present invention generally provides a method of treatment and improvement of quality of life for patients adversely affected by various pain conditions. One preferred embodiment provides a method of treatment of acute pain, moderate to moderately severe pain, chronic pain, non-cancer pain, osteoarthritic pain, bunionectomy pain or lower back pain in a patient in need thereof, comprising providing at least one or two dosage form having about 15 mg of hydrocodone and its salt and about 500 mg of acetaminophen, once, twice or thrice daily.
Abbvie Inc.


04/28/16
20160115487 

Cell-free synthetic incorporation of non-natural amino acids into proteins


The present disclosure provides methods for incorporating at least one non-natural amino acid into a polypeptide using a cell-free protein synthesis which includes a cell-free extract and is deficient in endogenous trna. The methods include providing the synthesis system with at least one non-natural amino acid, at least one orthogonal trna and one orthogonal aminoacyl-trna synthetase which aminoacylates the corresponding orthogonal trna with the non-natural amino acid.
Brigham Young University


04/28/16
20160115463 

Codon modified amylase from bacillus akibai


The present invention relates to an isolated synthetic polynucleotide encoding the mature amylase ax856 from bacillus akibai, using codon modified polynucleotide constructs for the expression of the amylase.. .
Novozymes A/s


04/21/16
20160108372 

Pestivirus replicons providing an rna-based viral vector system


Replicons of pestiviruses, in particular replicons of swine fever virus, are engineered to have a defective replication thereby having lost infectivity, and further containing a foreign gene. A replicon contains all the genetic information required for its replication, but lacks essential codons or all codons of at least one of the genes encoding the viral structural proteins e1, e2, ems or c protein, and consequently cannot generate infectious virus particles.

04/21/16
20160106740 

Treating pain in patients with hepatic impairment


An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.

04/21/16
20160106739 

Treating pain in patients with hepatic impairment


An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.

04/21/16
20160106738 

Treating pain in patients with hepatic impairment


An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.

04/14/16
20160102128 

Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells


The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

04/07/16
20160096875 

Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells


The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

04/07/16
20160095853 

Use of binders for manufacturing storage stable formulations


The present invention relates to storage stable prolonged release pharmaceutical dosage forms comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof, the manufacture thereof as well as their use for administration to human beings.. .
Purdue Pharma L.p.


03/24/16
20160083763 

Method of random circular permutation by mucp-isc and mucp-issc transposons


A method for designing circular permuted proteins using two engineered mu transposons for easy construction of random circular permuted proteins, the two designed transposons being mucp-isc (mu circular permutation transposon with integrated start codon) and mucp-issc (mu circular permutation transposon with integrated start and stop codon).. .
New York University


03/24/16
20160083748 

Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof


Described herein are synonymously altered gene sequences which express protein in differing levels within secretory as compared to non-secretory target tissue. An expression cassette comprising an open reading frame (orf) for a protein under the control of regulatory sequences which direct expression of the product in cell, which orf has been modified to preferentially increase expression levels in a selected tissue, wherein the modified orf is characterized by a triplet frequency of any one of tables 3-12, 16 or 17..
The Trustees Of The University Of Pennsylvania


03/24/16
20160083462 

Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same


The present invention relates to compositions and methods for creation of vector nucleic acid sequences (e.g., retroviral nucleic acid sequences) that comprise two or more exogenous nucleic acid sequences that encode highly homologous (e.g., identical) polypeptide sequences, yet wherein at least one of the exogenous nucleic acid sequences has been mutated using degenerate codons for purpose of reducing homology between the two or more exogenous nucleic acid sequences while maintaining the encoded polypeptide sequence. Preferred nucleic acid sequences include those encoding multi-chimeric immune receptor (cir) genes.
Roger Williams Hospital


03/24/16
20160083393 

Compounds for treatment of pain


The aspects of the disclosed embodiments are directed to novel compounds, specifically, quaternary ammonium derivatives of tertiary amine containing opioid drug compounds such as hydrocodone, hydromorphone and oxycodone, formulations containing said. Compounds or pharmaceutically acceptable salts thereof, which are capable of providing controlled release of the opioid drug upon administration to a patient in order to treat pain..

03/17/16
20160076052 

Design synthetic genes


The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a gc content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a gc content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes..
Jnc Corporation


03/03/16
20160058680 

Method and apparatus of manufacturing cosmetic products for regenerating skin cell


A method of manufacturing a cosmetic product for regenerating a skin cell including generating a water into a magnetized hexagonal water through a magnetized hexagonal water generator, separating a body fat stem cell from a body skin through a first extractor to extract a natural protein from a culture medium of a stem cell including the adipose-derived stem cell, extracting at least one skin beneficial ingredient from the culture medium of the stem cell through a second extractor, extracting a plant extract from at least one plant of a pomegranate, red ginseng, liquorice, ginseng seed, milk vetch, poria cocos, scutellaria, portulaca oleracea, pleuropterus multiflorus, angelica, angelica tenuissima, coix, codonopsis, morus alba and cucumber, and mixing the magnetized hexagonal water, natural protein, the at least one skin beneficial ingredient and the at least one plant extract through a mixer to manufacture a cosmetic product for regenerating a skin cell.. .
Aphrozone Co., Ltd.


02/25/16
20160051659 

Gene optimized hantaan virus m segment dna vaccine for hemorrhagic fever with renal syndrome


A synthetic, codon-optimized hantaan virus (htnv) full-length m gene open reading frame that consists of a unique nucleotide sequence encoding htnv proteins. This synthetic gene was cloned into a plasmid to form the first optimized htnv full-length m gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized puumala virus (puuv) dna vaccine.
Government Of The United States, As Represented By The Secretary Of The Army




Codon topics: Hydrocodone, Nucleic Acid, Acetaminophen, Carboxylic Acid, Benzoic Acid, Genetically, Recombinant, Amino Acid, Nucleotide, Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitor, Reverse Transcriptase, Antibodies, Base Sequence, Replication

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.8348

4371

3 - 0 - 101